Patient Derived Xenograft (PDX) Models Market Report 2024

The patient derived xenograft (PDX) models market size has grown rapidly in recent years. It will grow from $0.35 billion in 2023 to $0.4 billion in 2024 at a compound annual growth rate (CAGR) of 16%. The growth during the historical period can be attributed to investments in research and development, regulatory support, partnerships and collaborations, an increasing number of contract research organizations (CROs), and a rising number of cancer cases.

The patient derived xenograft (PDX) models market size is expected to see rapid growth in the next few years. It will grow to $0.74 billion in 2028 at a compound annual growth rate (CAGR) of 16.1%. The growth in the forecast period can be attributed to the demand for personalized medicine, an increase in demand for humanized PDX models, a growing incidence of cancer, a focus on precision oncology, and increased R&D investment for cancer research. Major trends during this period include technological developments, rising demand for humanized PDX models, collaborative research initiatives, growing investments in cancer research, and an increasing focus on immuno-oncology.

The demand for personalized medicine is expected to drive the growth of the patient-derived xenograft (PDX) models market. Personalized medicine tailors medical treatments to individual patient characteristics, such as genetics, environment, and lifestyle. This demand is rising due to advancements in genomic research, which facilitate treatments based on individual genetic profiles, leading to more effective and targeted healthcare. PDX models support personalized medicine by testing individual patient tumors to predict treatment responses and tailor therapies. For example, in February 2024, the Personalized Medicine Coalition (PMC) reported that the FDA approved 16 new personalized treatments for rare diseases in 2023, a significant increase from six approvals in 2022. Thus, the demand for personalized medicine fuels the growth of the PDX models market.

Major companies in the PDX models market are developing innovative models with in vivo bioluminescence imaging capabilities for real-time tumor growth monitoring. This imaging technique enhances PDX models by enabling non-invasive monitoring of tumor metastasis and treatment responses, improving the effectiveness of preclinical drug development research. For instance, in March 2024, InVitro Research Solutions Private Limited, an Indian Contract Research Organization (CRO), launched an innovative orthotopic model of human glioblastoma in NSG-SGM3 mice using PDX and in vivo bioluminescence imaging. This model aims to enable personalized treatment of glioblastoma, a highly aggressive brain cancer, and is critical for understanding glioblastoma biology and evaluating new targeted therapies and immunotherapies to improve outcomes.

In November 2021, Inotiv Inc., a US-based provider of nonclinical and analytical drug discovery development services, research models, and related products, acquired Envigo RMS Holding Corp. for $271 million. This acquisition aims to improve efficiency, reduce lead times, and offer a variety of research models and services. Envigo RMS Holding Corp. is a US-based provider of research models and services.

Major companies operating in the patient derived xenograft (PDX) models market are Laboratory Corporation of America Holdings, WuXi AppTec Co. Ltd., Charles River Laboratories International Inc., The Jackson Laboratory, Inotiv Inc, Biocytogen Pharmaceuticals Co. Ltd., Taconic Biosciences Inc, BioDuro-Sundia Inc, Horizon Discovery Ltd., Crown Bioscience Inc., Champions Oncology Inc., Oncodesign Services S.A, Genesis Biotechnology Group LLC., Creative Animodel, Abnova Corp., Certis Oncology Solutions Inc., Xentech, Aragen Bioscience Inc., EPO Experimental Pharmacology & Oncology Berlin-Buch GmbH., Urosphere, Hera BioLabs, InnoSer, Pharmatest Services Ltd., IVRS AB, Altogen Inc.

North America was the largest region in the patient derived xenograft (PDX) models market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the patient derived xenograft (PDX) models market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the patient derived xenograft (PDX) models market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Patient-derived xenograft (PDX) models involve the transplantation of human tumor tissue into immunodeficient animal hosts. These models replicate the complexity of human tumors more accurately than traditional cell line models. PDX models are essential for studying tumor biology and testing potential cancer therapies before they reach clinical trials.

The primary types in the patient-derived xenograft (PDX) models market are mice models and rat models. Mice models are laboratory mice that have been genetically modified or bred to study specific biological processes, diseases, or treatment responses, supporting biomedical and pharmaceutical research. The various techniques include heterotopic implantation and orthotopic implantation, and encompass several types of tumors such as gastrointestinal tumor models, lung tumor models, hematological tumor models, gynecological tumor models, respiratory tumor models, urological tumor models, and others. PDX models are used in preclinical drug development, precision medicine, co-clinical trials, and basic cancer research by academic institutions, research organizations, pharmaceutical companies, biotechnology firms, and other entities.

The patient derived xenograft (PDX) models market research report is one of a series of new reports that provides patient derived xenograft (PDX) models market statistics, including the patient derived xenograft (PDX) models industry global market size, regional shares, competitors with patient derived xenograft (PDX) models market share, detailed patient derived xenograft (PDX) models market segments, market trends, and opportunities, and any further data you may need to thrive in the patient derived xenograft (PDX) models industry. These patient derived xenograft (PDX) models market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The patient derived xenograft (PDX) models market includes revenues earned by entities by providing services such as evaluating drug efficacy, studying tumor biology, and predicting patient-specific treatment responses in preclinical cancer research. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.